IXHL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Incannex Healthcare Inc (IXHL.O) is -5.40, compared to its 5-year average forward P/E of -203.69. For a more detailed relative valuation and DCF analysis to assess Incannex Healthcare Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-203.69

Current PE

-5.40

Overvalued PE

210.20

Undervalued PE

-617.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.68

Current EV/EBITDA

-4.29

Overvalued EV/EBITDA

0.81

Undervalued EV/EBITDA

-2.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23738.52

Current PS

0.00

Overvalued PS

59486.49

Undervalued PS

-12009.45

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IXHL News & Events

Events Timeline

No data

News

9.0

2025-12-03Newsfilter

Incannex Secures FDA Fast Track Designation for IHL-42X in OSA Treatment

9.0

2025-12-03NASDAQ.COM

What’s Driving Incannex's Pre-market Surge?

4.0

2025-12-01NASDAQ.COM

Reasons to Consider Incannex Healthcare Inc. (IXHL) as a New Investment Opportunity

People Also Watch

Frequently Asked Questions

What is Incannex Healthcare Inc (IXHL) stock price today?

The current price of IXHL is 0.396 USD — it has decreased -0.5 % in the last trading day.

What is Incannex Healthcare Inc (IXHL)'s business?

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

What is the price predicton of IXHL Stock?

Wall Street analysts forecast IXHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IXHL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Incannex Healthcare Inc (IXHL)'s revenue for the last quarter?

Incannex Healthcare Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Incannex Healthcare Inc (IXHL)'s earnings per share (EPS) for the last quarter?

Incannex Healthcare Inc. EPS for the last quarter amounts to -0.02 USD, decreased -93.55 % YoY.

What changes have occurred in the market's expectations for Incannex Healthcare Inc (IXHL)'s fundamentals?

The market is revising No Change the revenue expectations for Incannex Healthcare Inc. (IXHL) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.12%.

How many employees does Incannex Healthcare Inc (IXHL). have?

Incannex Healthcare Inc (IXHL) has 12 emplpoyees as of January 10 2026.

What is Incannex Healthcare Inc (IXHL) market cap?

Today IXHL has the market capitalization of 137.11M USD.